-Reuters
Wedbush Initiates Coverage On Rani Therapeutics Hldgs with Outperform Rating, Announces Price Target of $28
Wedbush analyst Andreas Argyrides initiates coverage on Rani Therapeutics Hldgs (NASDAQ:RANI) with a Outperform rating and announces Price Target of $28.